Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
BMJ Case Rep ; 14(1)2021 Jan 29.
Artículo en Inglés | MEDLINE | ID: mdl-33514621

RESUMEN

Around the world, with the availability of factor concentrates, patients with haemophilia have undergone major and minor surgeries. Inhibitor development in early postoperative period leading to inadequate factor recovery and ongoing bleeding is a nightmare for both operating surgeon as well as haematologists. We describe a case of an elderly man with mild haemophilia A, who was diagnosed with pancreatic carcinoma and underwent Whipple's procedure. After an uneventful procedure, he developed high-titre inhibitors and bleeding a week after surgery posing major challenges in his management. The case highlights the importance of experienced surgeons, trained haematologists, regular monitoring of factor assay/inhibitors, adequate factor and bypassing-agent support while performing such procedures.


Asunto(s)
Factores de Coagulación Sanguínea/antagonistas & inhibidores , Hemofilia A/inmunología , Neoplasias Pancreáticas/cirugía , Hemorragia Posoperatoria/tratamiento farmacológico , Anciano , Formación de Anticuerpos/inmunología , Factores de Coagulación Sanguínea/inmunología , Factor VIII/administración & dosificación , Factor VIII/uso terapéutico , Resultado Fatal , Hematología/normas , Hemofilia A/complicaciones , Humanos , Fragmentos Fc de Inmunoglobulinas/administración & dosificación , Fragmentos Fc de Inmunoglobulinas/uso terapéutico , Hemorragias Intracraneales/complicaciones , Masculino , Neoplasias Pancreáticas/complicaciones , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/inmunología , Hemorragia Posoperatoria/etiología , Proteínas Recombinantes de Fusión/administración & dosificación , Proteínas Recombinantes de Fusión/uso terapéutico , Factores de Riesgo , Cirujanos/estadística & datos numéricos , Neoplasias Pancreáticas
2.
Indian J Hematol Blood Transfus ; 37(4): 528-533, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-33250594

RESUMEN

In COVID 19 pandemic, delivery and access of health care services have become challenging. Telemedicine services can be considered for management of patients with hematological diseases. This study included all patients who enrolled for telemedicine facility for hematology from May 15 to July 15, 2020. Patient's demographic and disease related parameters were recorded during the teleconsultation call. Overall satisfaction of attending doctor and patients were also recorded. A total of 1187 teleconsultation appointments were taken, of which 944 (79.6%) were successfully attended. Median age of patients was 38 years (range- 0.5-78 years), with 38% females. 55% of successful calls were from patients suffering a malignant hematological disorder. 24% had an active complaint pertaining to their disease or treatment. Of these, 162 (17%) were asked for a physical consultation. A significant association was found between the requirement of physical consultation and diagnosis (p < 0.001), absence of active complaint (< 0.0001) and education level of responder (p = 0.008). Patients understand that teleconsultation is helpful in preventing COVID-19 infection (71.4%) and avoids outpatient department rush (14.5%) associated with physical appointments; and around 80% patients were satisfied with the teleconsult. With the emergence of COVID 19, many localities under partial lockdown with constant fear of contacting virus amongst patients and health care providers, we can clearly see the advantages as well as feasibility of telemedicine services for our patients. The acute surge in telemedicine could be harnessed in the future to provide comprehensive and integrated care to patients of hematological disorders.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...